1	Prevalence of Hyperglycemia in Pregnancy using early, standard and late screening: a
2	study in the Primary Care Health in Lima, Peru
3	
4	Authors
5	
6	S.N. Seclén ¹ (ORCID: 0000-0002-2431-099X)
7	Lucy Nelly Damas-Casani ² (ORCID : 0000-0002-8714-2217)
8	Vicky Delia Cecilia Motta-Montoya ¹
9	Sandra Lesly Jiménez-Martel ^{1,3}
10	Marlon Yovera-Aldana ⁴ . (ORCID: 0000-0002-1947-7736)
11	
12	Affiliations
13	1 Universidad Peruana Cayetano Heredia, Lima, Perú
14	2 Endocrinology Service, Hospital María Auxiliadora, Lima, Perú
15	3 Endocrinology Service, Hospital Santa Rosa, Lima, Perú
16	4 Grupo de Investigación de Neurociencias, Metabolismo y Efectividad clínica y

Corresponding author 19

17

18

E-mail: myovera@cientifica.edu.pe (MYA) 20

Sanitaria, Universidad Científica del Sur, Lima, Perú

perpetuity.

It is made available under a CC-BY 4.0 International license.

Abstract

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

Objective: To determine the prevalence of hyperglycemia in pregnancy (HIP) based on the timing of screening in pregnant women. Materials and Methods: A cross-sectional study was conducted on pregnant women recruited from February 2019 to August 2022 in four primary care centers in Lima, excluding those with known diabetes. Screening involved an Oral Glucose Tolerance Test with 75 g of glucose at the first contact. It was classified as early if performed before 24 weeks, standard between 24-28 weeks, and late if after 29 weeks. For gestational diabetes mellitus (GDM), we used the IADPSG diagnostic criteria for any gestational age. For diabetes in pregnancy (DIP), glucose levels over 126 mg/dl fasting or over 200 mg/dl at 2 hours post-load were used. We calculated prevalence ratios for GDM and DIP based on the type of screening. Results: We included 4,495 pregnant women with an average age of 29 years. The prevalence of HIP was 14.9%, GDM was 14.2%, and DIP was 0.7%. Early GDM screening showed a 23% higher prevalence compared to GDM screening at 24-28 weeks. adjusted for age (PR 1.23; 95% CI 1.01 – 1.49; p=0.036). No differences were found for DIP across screening types. **Conclusion:** In pregnant women at four primary centers in Lima, one in seven pregnant women (14.9%) had HIP, GDM was 14.2%, and DIP was 0.7%.. Early screening showed the highest proportion of GDM compared to standard or late screening. Longitudinal studies are needed to validate whether this higher early prevalence impacts maternalperinatal complications. Key words (MeSH): Diabetes, gestacional; mass screening; prevalence study; glucose tolerance test; Peru;

it is made available under a CC-DT 4.0 international license

Introducción

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

Globally, approximately 16.7% of pregnancies present hyperglycemia in pregnancy (HIE), defined as any known pre-existing alteration or first diagnosed during gestation. Of these cases, 80.3% are due to gestational diabetes mellitus (GDM). The prevalence of HIE progressively increases with age and 80% originating in low- to middle-income countries where access to healthcare is limited. [1] HIE is associated with maternal and perinatal complications. [2] Normalizing blood glucose levels in patients with GDM and diabetes in pregnancy (DIP) through lifestyle changes, and in some cases pharmacological treatment, has been shown to reduce maternal-perinatal complications by more than 60%. [3] In the last two decades, the increase in the prevalence of GDM has ranged from 16% to 127%. This is attributed to the progressive rise in obesity by unhealthy lifestyles, greater governmental efforts to conduct universal screening and a diagnostic threshold criteria diminished[4]. In Peru, the prevalence of overweight and obesity in women of reproductive age is 37% and 28%, respectively[5]. Consequently, nearly 50% of pregnant women have excess weight in the first trimester, making it one of the main risk factors for the development of GDM. [6] Moreover, the new International Association of the Diabetes and Pregnancy Study Groups (IADPSG) criteria, have increased the frequency of GDM by as much as 6 to 11 times [7]. However, the diagnosis and treatment are cost-effective when considering postpartum outcomes for both the mother and the child. [8–10]. The International Federation of Gynecology and Obstetrics (IFGO) proposes different strategies to implement universal screening depending on the resources available in each country. Standard screening in the first trimester includes only fasting glucose; however, it suggests that in high-risk populations, an oral glucose tolerance test

perpetuity.

It is made available under a CC-BY 4.0 International license.

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

(OGTT) with 75 g could be performed at the initial visit, repeating it at 24-28 weeks if the first result is negative. [11] Thus, waiting until that gestational age to initiate treatment could delay a potential improvement in the rate of complications, similar to the preventive action of acetylsalicylic acid to prevent preeclampsia. [12] Recent studies suggest that abnormal, non-diabetic fasting glucose values in early screening impact complications. [13] Both early hyperglycemia and DIP are associated with worse outcomes than GDM diagnosed by standard methods. [14,15] On the other hand, treating GDM identified by IADPSG criteria using OGTT before 22 weeks in pregnant women with at least one risk factor for GDM, has been shown to reduce neonatal outcomes, although it does not affect those related to hypertensive disorders. [16] However, despite the diversity of criteria for GDM, there is no consensus on firsttrimester hyperglycemia, with its nomenclature being variable and complicating comparison between regions. [17] In Lima-Peru, a study conducted in a reference center using universal screening between 24-28 weeks with IADPSG criteria found a prevalence of 16%. [18] This prevalence, which is close to the global average, could differ if evaluated in primary care health facilities, especially if early OGTT (before 24 weeks) is applied. Therefore, the objective of this study is to determine the prevalence of hyperglycemia during pregnancy in four

primary care centers in South Lima at the first contact using OGTT.

Matherial and Methods

Study Design and clinical setting

A cross-sectional study was conducted analyzing data from the Gestational Education in Diabetes (GEIDI) program implemented in four maternal and child health centers in South Lima. The GEIDI program is an early diagnosis and educational intervention strategy aimed at pregnant women diagnosed with gestational diabetes through the oral glucose tolerance test (OGTT) during their initial contact. This program was funded by the World Diabetes Foundation (WDF) and executed by a professional and technical team from the Peruvian Juvenile Diabetes Association (ADJ in Spanish) and the María Auxiliadora Hospital. Interventions were carried out at the José Carlos Mariátegui Maternal and Child Center (JCM) in Villa María del Triunfo district, San Genaro Maternal and Child Center (SG) and the Virgen del Carmen Maternal and Child Center (VC) in Chorrillos district and Manuel Barreto Maternal and Child Center (MB) in San Juan de Miraflores district. Pregnant women were recruited from February 2019 to August 2022.

Population, sample and sampling

Pregnant women attended at the four primary care centers, aged 15 years or older, Peruvian nationality, and having resided in the district for more than six months, were included in the study. Fasting glucose screening is part of the procedures of the Ministry of Health in maternal care, but it was applied for the first time in this population through the oral glucose tolerance test (OGTT) using 75 gr of glucose. Patients with known diabetes mellitus prior to pregnancy, uncertain last menstrual period or not confirmed by ultrasound performed before 24 weeks of gestation, and multiple pregnancies were excluded. The sampling

perpetuity.

It is made available under a CC-BY 4.0 International license .

method was non-probabilistic census, accepting all pregnant women who met the eligibility criteria based on the provided data.

Variables

Hyperglycemia in Pregnancy: For this study, diabetes in pregnancy was defined as having fasting glucose values greater than 126 mg/dl (7.0 mmol/l) or values greater than 200 mg/dl (11.1 mmol/l) at 2 hours, at any gestational age. For gestational diabetes mellitus (GDM), we applied the HAPO criteria, where a diagnosis was positive if fasting glucose was between 92 and 125 mg/dl (5.1 to 6.9 mmol/l), glucose at 1 hour was greater than 180 mg/dl (9.9 mmol/l), and glucose at 2 hours was between 153 and 199 mg/dl (8.5 to 11.0 mmol/l), with at least one positive result being sufficient.

Other Variables: Based on the gestational age during the OGTT, the timing of screening was classified as early (24 weeks or less), standard (24-28 weeks), and late (more than 28 weeks). The year of the OGTT (2019, 2020, 2021, 2022) and age group (less than 18; 18 to 24.9; 25 to 29.9; 30 to 34.9; 35 to 39.9; 40 to 44.9; and 45 or more) were also recorded.

Procedures

The GEIDI program scheduled an Oral Glucose Tolerance Test with 75 g of anhydrous glucose during the first contact of the pregnant woman with the health center, obtaining three venous samples: baseline, at 1 hour, and at 2 hours. Glucose was measured using the glucose oxidase method, employing a Wiener reagent with a coefficient of variation <2%, following standard guidelines for analysis. An online reporting system was established for laboratory results registration. After diagnosis, clinical management was based on the guidelines from the Ministry of Health. Additionally, educational sessions were provided for nutritional management and tools for glycemic self-monitoring were

supplied through the donation of glucose meters. Pregnant women were referred to the Hospital María Auxiliadora for evaluation by endocrinology and gynecology if the maternal-infant health centers lacked the necessary specialty or if the patient required evaluation at a higher-level facility. For the study, the authors' team requested the laboratory results data of the screened pregnant women from the GEIDI program coordinators. This information was provided without identifying data such as names or national identity document numbers. Data were evaluated and analyzed from January 15 to March 30, 2024 and included age, date of the OGTT, gestational age, source health center, and the glucose values from the OGTT.

Analysis plan

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

The health center of origin, age group, gestational age at the time of the oral glucose tolerance test (OGTT), and the type of screening performed were described using absolute and relative frequencies. Additionally, the proportion of altered glycemia, the total number of glucose measurements, and the type of glycemic alteration were calculated. The demographic characteristics of pregnant women were compared based on the timing of screening: early (less than 24 weeks), standard (24-28 weeks), and late (more than 28 weeks). Crude and age-adjusted prevalence ratios for the occurrence of GDM or diabetes in pregnancy (DIP) were calculated according to the screening strategy using Poisson regression with robust variances. By the same method, the prevalence ratio for GDM or DIP by age group and year of diagnosis was also calculated. Statistical analysis was performed using Stata version 18.1 (Stata Corp, College Station, Texas, USA), with a

significance level set at 0.05 for all hypothesis tests.

Ethical considerations

- This protocol was evaluated by the Ethics Committee of the Universidad Peruana 158
- Cayetano Heredia, with registration code 200797 and certificate 646-01-21. Patient 159
- 160 confidentiality was maintained through the anonymization of records..

Results

161

162

163

164

165

166

167

168

169

172

173

175

176

177

178

179

180

181

182

183

The study was conducted from February 2019 to August 2022, with a total of 4,710 pregnant women screened. 4,495 met the inclusion and exclusion criteria. From the selected group, 2,590 (57.6%) underwent early screening, 901 (20.0%) standard screening, and 1,004 (22.4%) late screening (Figure 1). The restrictions imposed in 2020 due to the COVID-19 pandemic led to a decrease in the screening rate; however, this rate recovered in 2021 and 2022.

- Figure 1. Selection flowchart of the GEIDI Program for the calculation of the
- prevalence of gestational diabetes mellitus 170
- 171 OGTT: Oral Glucose Tolerance Test. DM: Diabetes mellitus

General Characteristics

The screened pregnant population was predominantly young, with 78.1% between 18 and 174

35 years. Regarding OGTT results, abnormal fasting glucose levels were found in 539

pregnant women (12.0%), representing the highest percentage of altered results.

Abnormal glucose levels at 1 hour were identified in 193 women (4.2%), and abnormal

glucose levels at 2 hours were found in 97 women (2.1%)

Breaking down these findings, it was observed that among the screened pregnant

population, only 542 (12.1%) exhibited altered fasting glucose levels, either in isolation

or in combination with postprandial glucose levels, and only 127 (2.8%) showed

alterations in postprandial glucose levels (Table 1).

Table 1. Characteristics of pregnant women screened

1 8	
Characterstics	N (%)
Total	4495 (100.0)
Age (years)	
Media DE	
< 18	121 (2.7)
18 – 24.9	1319 (29.3)
25 – 29.9	1245 (27.7)
30 – 34.9	950 (21.1)
35 – 39.9	627 (13.9)
40 – 44.9	213 (4.7)
45 and over	20 (0.4)
Health care facility	
Jose Carlos Mariátegui VMT	2400 (53.4)
Manuel Barreto SJM	343 (7.6)
San Genaro – Chorrillos	1233 (27.4)
Virgen del Carmen –Chorrillos	519 (11.6)
Screening year	
2019	1953 (43.5)
2020	657 (14.6)
2021	1298 (28.9)
2022	587 (13.1)
Screening gestational age	
8 or less	477 (10.6)
9 a 12	723 (16.1)
13 a 16	559 (12.4)
17 a 23	831 (18.5)
24 a 28	898 (19.9)
29 a 32	492 (10.9)
32 a 36	413 (9.2)
37 and over	102 (2.3)
Screening time	
Early	2590 (57.6)
Standard	898 (20.0)
Late	1007 (22.4)

Blood glucose	
Fasting glucose	
Less than 92 mg/dl(5.1 mmol/l)	3956 (88.0)
92 to 125.9 mg/dl (5.1 to 6.9 mmol/l)	520 (11.6)
126 and over (7 mmol/l)	19 (0.4)
Blood glucose at 1 hour	
Less than 180 mg/dl (9.9 mmol/l)	4302 (95.7)
180 and over (10 mmol/l)	193 (4.3)
Blood glucose at 2 hours	
Less than 153 (8.5 mmol/l)	4398 (97.8)
153 to 199.9 mg/dl (8.5 to 11.0 mmol/L)	74 (1.7)
200 and over (11.1 mmol/l)	23 (0.5)
Type of glycemic alteration	
No	3826 (85.1)
Basal only	441 (9.8)
Basal and postprandial	101 (2.3)
Postprandial only(s)	127 (2.8)

The pregnant women included in the three screening strategies had comparable ages (p=0.213). The early screening strategy exhibited the highest proportion of altered fasting glucose, with 13.5%, compared to 9.9% in the standard screening and 9.8% in the late screening (p=0.010) (Table 2).

187

188

189

190

191

192

193

194

Table 2. Demographic characteristics according to screening strategy in pregnant women.

	Early screening	Standard	Late screening	p-value
		screening		
General	2590	898	1007	
Age (years)				
(Media ± SD)	28.3 ± 6.6	28.1 ± 6.6	28.0 ± 6.4	0.310 a
Age group				

< 18	80 (3.1)	15 (1.7)	26 (2.6)	
18 – 24.9	717 (27.7)	291 (32.4)	311 (30.9)	
25 – 29.9	752 (29.0)	244 (27.2)	249 (24.7)	
30 – 34.9	529 (20.4)	169 (18.8)	252 (25.0)	
35 – 39.9	368 (14.2)	129 (14.4)	130 (12.9)	
40 – 44.9	129 (5.0)	46 (5.1)	38 (3.8)	
45 and over	15 (0.6)	4 (0.5)	1 (0.1)	
Health care facility, n(%)				
Jose Carlos Mariátegui VMT	675 (26.1)	344 (38.3)	214 (21.3)	<0.001 a
Manuel Barreto SJM	1437 (55.5)	362 (40.3)	601 (59.7)	
San Genaro – Chorrilos	270 (10.4)	125 (13.9)	124 (12.3)	
Virgen del Carmen - Chorrillos	208 (8.0)	67 (7.5)	68 (6.8)	
Screening year, n(%)				
2019	1140 (44.0)	385 (42.9)	428 (42.5)	<0.001 a
2020	407 (15.7)	132 (14.7)	118 (11.7)	
2021	668 (25.8)	284 (31.6)	346 (34.4)	
2022	375 (14.5)	97 (10.8)	115 (11.4)	
Casting glucose , (Media ± SD)				
mg/dl	80.5 ± 13.1	78.5 ± 10.0	77.7 ± 11.3	<0.001 a
mmol /l	4.51 ± 0.73	4.36 ± 0.56	4.31 ± 0.63	
Blood glucose at 1 hour (Media ± SD)				
mg/dl	120 ± 32.8	119.3 ± 29.9	121.9 ± 29.8	0.161 a
mmol /l	6.66 ± 1.82	6.62 ± 1.66	6.77 ± 1.65	
Blood glucose at 2 hours (Media ± SD)				
mg/dl	96.1 ± 24.7	96.7 ± 23.2	95.7 ± 22.7	0.646 a
mmol /l	5.33 ± 1.37	5.37 ± 1.29	5.31 ± 1.266	
Fasting glucose category, n (%)				
Less than 92 mg/dl (5.1 mmol/l)	2239 (86.5)	809 (90.1)	908 (90.2)	0.005 °
92 to 125.9 mg/dl (5.1 to 6.9 mmol/l)	337 (13.0)	86 (9.6)	97 (9.6)	
126 mg/dl and over (7 mmol/l)	14 (0.5)	3 (0.3)	2 (0.2)	
Blood glucose at 1 hour category, n (%)				
Less than 180 mg/dl (9.9 mmol/l)	2481 (95.8)	857 (95.0)	964 (96.1)	0.901 b
180 mg/dl and over (10 mmol/l)	109 (4.2)	41 (4.6)	43 (4.3)	
Blood glucose at 2 hours category, n (%)				
Less than 153 mg/dl (8.5 mmol/l)	2534 (97.8)	874 (97.3)	990 (98.3)	0.338 °
153 to 199.9 mg/dl (8.5 to 11.0				
133 to 199.9 flig/di (8.3 to 11.0	40 (1.5)	21 (2.3)	13 (1.3)	

1	2
1	2

200 mg/dl and over (11.1 mmol/l)	16 (0.6)	3 (0.3)	4 (0.4)	
Type of glycemic alteration, n (%)				
No	2167 (83.7)	779 (86.6)	880 (87.4)	0.007 b
Basal only	294 (11.4)	69 (7.7)	78 (7.8)	
Basal and postprandial	60 (2.3)	20 (2.2)	21 (2.1)	
Postprandial only(s)	69 (2.7)	30 (3.3)	28 (2.8)	

VMT villa María del Triunfo. SJM: San Juan de Miraflores a Anova One way b Pearson chi square test c Fisher exact test

Prevalence of Hyperglycemia in Pregnancy

A general prevalence of hyperglycemia in pregnancy was found to be 14.9% (95% CI 13.9 -15.9), with gestational diabetes mellitus (GDM) at 14.2% (95% CI 13.2 - 15.3) and diabetes in pregnancy at 0.7% (95% CI 0.5 - 0.9). Of these cases, 95.5% corresponded to GDM (60.2% identified before 24 weeks and 35.3% after 24 weeks), while 4.5% presented with diabetes in pregnancy (Table 3).

Table 3. Prevalence of hyperglycemia in pregnancy of screened pregnant women in four centers in South Lima.

Tipo de hiperglicemia en embarazo	Prevalence ^a	CI 95%	Prevalence ^b	CI 95%
	n (%)		%	
No	3826 (85.1)			
Hiperglicemy in pregnancy	669 (14.9)	(IC95% 13.9 -15.9)	100%	
Gestational diabetes	639 (14.2)	(IC95% 13.2 – 15.3)	95.5%	(IC95% 93.7 – 96.9)
Early GDM	403 (8.9)	(IC95% 8.1 – 9.8)	60.2%	(IC95% 56.4 – 63.9t)
Standard GDM	113 (2.5)	(IC95% 2.1 – 3.0)	16.9%	(IC95% 14.1 -19.9)
Late GDM	123 (2.7)	(IC95% 2.2 – 3.2)	18.4%	(IC95% 15.5 – 21.5)
Diabetes in pregnancy	30 (0.7)	(IC95% 0.5 - 0.9).	4.5%	(IC95% 3.0 – 6.3)
Early DIP	20 (0.4)	(IC95% 0.2 – 0.6)	3.0%	(IC95% 1.8 – 4.5)
Standard DIP	6 (0.1)	(IC95% 0.05 – 0.3)	0.9%	(IC95% 0.3 – 1.9)
Late DIP	4 (0.1)	(IC95% 0.02 – 0.2)	0.6%	(IC95% 0.1 – 1.5)

196 197

198

199

200

201

202

203

204

205

206

^a taking as a denominator the total of 4495 pregnant women. ^b Taking as a denominator the totality of 669 pregnant women with HIP According to the timing of the screening, early showed a higher frequency of gestational diabetes at 26%, compared to standard x(PR 1.26; 95% CI 1.01 – 1.51; p=0.035) (**Table** 4). Tables S2 and S3 provide a description of the patients with GDM and DIP,

Table 4. Prevalence ratios of glycemic results according to type of screening

	n/N	Prevalence (CI 95%)	Crude	p-value	Ajusted*	p-value
Gestational diabetes						
Early screening ^a	403 / 2570	15.7 (14.3 – 17.1)	1.23 (1.01 -1.50)	0.031	1.23 (1.01 – 1.49)	0.036
Standard screening b	113 / 892	12.7 (10.6 – 15.0)	1.00		1.00	
Late screening ^c	123 / 1003	12.3 (10.3 – 14.5)	0.96 (0.76 – 1.22)	0.790	0.97 (0.76 – 1.23)	0.820
Diabetes in pregnancy						
Early screening ^a	20/2590	0.77 (0.47 – 1.19)	1.15 (0.46 – 2.86)	0.755	1.13 (0.46 – 2.80)	0.790
Standard screening b	6 / 898	0.67 (0.25 – 1.45)	1.00		1.00	
Late screening c	4 /1007	0.39 (0.11 – 1.01)	0.59 (0.17 – 2.10)	0.419	0.62 (0.17 – 2.23)	0.474

PRc: Crude prevalence ratio. RPa: Adjusted prevalence ratio.

Hyperglycemia before 24 weeks

- When the OGTT was performed before 24 weeks (early screening), the prevalence of GDM in 2020 showed a decrease of 34% compared to 2019. Subsequently increased a 45% in 2021 and a 92% in 2022. Regarding diabetes in pregnancy (DIP), no significant differences were observed among the years. Additionally,
- 225 A progressive increase in GDM was evident with advancing age, starting from 30 years.
- This trend was statistically significant only in the age group of 30 to 40 years (**Table 5**). 226

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

respectively.

^{*} Age adjusted. a Before 24 weeks. b Between 24 -28 weeks. c After 28 weeks

tio made available under a CC B1 4.0 international license

Hyperglycemia after 24 weeks

For the OGTT conducted between 24 and 28 weeks (standard screening), the prevalence of GDM decreased in 2020, followed by increases of 24% and an astonishing 102% in 2021 and 2022, respectively. On the other hand, when the OGTT was performed after 28 weeks (late screening), a higher increase in prevalence was observed, with increases of 62% and 130% for the same years. In standard screening, it was notable that the age group of 30 to 35 years exhibited a 75% increase in prevalence (PR 1.75; 95% CI 1.1-2.76; p=0.032) (**Table 5**).

Table 5. Prevalence ratios of glycemic results according to year, health center and age group of each screening strategy.

	Early			Standard			Late		
	screening			screening			screening		
	Prevalence	PR (CI 95%)	p-value	Prevalence	PR (CI 95%)	p-value	Prevalence	PR (CI 95%)	p-value
Gestational diabetes									
Screening year									
2019	12.3 (139 /1134)	1.00		12.3 (43/384)	1.00		9.8 (42/428)	1.00	
2020	9.4 (38/404)	0.76 (0.54 – 1.08)	0.127	3.4 (9/132)	0.61 (0.31 – 1.21)	0.012	7.7 (9/117)	0.78 (0.39 – 1.56)	0.594
2021	19.4 (128/ 659)	1.58 (1.27 – 1.97)	<0.001	15.3 (39/279)	1.24 (0.83 – 1.87)	0.283	16.0 (55/344)	1.62 (1.09 – 2.39)	0.015
2022	26.7 (98/ 373)	2.14 (1.70 – 2.69)	<0.001	16.5 (22/97)	2.02 (1.27 – 3.21)	0.003	14.9 (17/114)	2.30 (1.41 – 3.76)	0.001
Age group									
< 18 años	8.8 (7/ 80)	0.64 (0.31 – 1.34)	0.242	6.7 (1/ 15)	0.64 (0.09 – 4.37)	0.655	7.7 (2/ 26)	0.81 (0.20 – 3.19)	0.747
18 – 24.9	13.6 (97/716)	1.00		10.3 (30/290)	1.00		9.5 (30/311)	1.00	
25 – 29.9	13.9 (104/747)	1.02 (0.79 – 1.32)	0.835	11.9 (29/244)	1.00 (0.61 – 1.64)	0.572	12.2 (27/249)	1.12 (0.69 – 1.83)	0.642
30 – 34.9	17.9 (94/523)	1.32 (1.02 – 1.72)	0.033	17.4 (29/167)	1.75 (1.11 – 2.76)	0.032	14.3 (38/252)	1.56 (0.99 – 2.44)	0.051
35 – 39.9	20.6 (75/364)	1.52 (1.15 – 1.99)	0.003	15.9 (20/126)	1.58 (0.93 – 2.68)	0.111	14.5 (19/127)	1.55 (0.91 – 2.65)	0.109
40 – 44.9	17.6 (22/115)	1.29 (0.85 – 1.98)	0.224	6.5 (3/ 46)	0.63 (0.20 – 1.98)	0.430	11.9 (7/ 37)	1.96 (0.92 – 4.14)	0.078
45 a más	27.7 (4/15)	1.96 (0.83 – 4.64)	0.123	25 (1/ 4)	2.41 (0.42 – 13.7)	0.318	0.0 (0/ 1)	NC	NC
Diabetes in pregnancy*									
Screening year									
2019	0.5 (6/1140)	1.00		0.3 (1/385)	1.00		0.0 (0/428)	NC	

2020	0.7 (3/ 407)	1.40 (0.35 – 5.57)	0.633	0.0 (0/132)	NC		0.8 (1/118)	NC
2021	1.4 (9/ 668)	2.56 (0.91 – 7.16)	0.073	2.9 (5/284)	6.78 (0.79 – 57.9)	0.080	0.6 (2/346)	NC
2022	0.5 (2/ 375)	1.01 (0.20 – 5.00)	0.987	0.8 (0/97)	NC		0.0 (1/115)	NC
Age group								
< 18 años	0.0 (0/ 80)	NC		0.0 (0/ 15)	NC		0.0 (0/26)	NC
18 - 24.9	0.1 (1/717)	1.00		0.3 (1/291)	1.00		0.0 (0/311)	NC
25 – 29.9	0.6 (5/752)	4.76 (0.55 – 40.7)	0.154	0.0 (0/244)	NC		0.0 (0/249)	NC
30 - 34.9	1.0 (6/529)	8.13 (0.98 – 67.4)	0.052	1.1 (2/169)	3.44 (0.31 – 36.9)	0.311	0.0 (0/252)	NC
35 – 39.9	1.2 (4/368)	7.79 (0.87 – 69.5)	0.066	3.4 (3/129)	6.76 (0.70 – 88.8)	0.096	1.5 (3/130)	NC
40 – 44.9	2.6 (4/129)	22.2 (2.54 – 197.5)	0.005	0.0 (0/46)	NC		2.3 (1/38)	NC
45 a más	0.0 (0/ 15)	NC		0.0 (0/ 4)	NC		0.0 (0/ 1)	NC

^{*}NO diabetes in pregnancy was the union of euglycemia and gestational diabetes

Discusión

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

Hyperglycemia in pregnancy is a condition that significantly impacts maternal and perinatal outcomes, and its screening in primary care is essential. In this study, we found that approximately 1 in 7 pregnant women (14.9%) presents this condition, excluding those with known diabetes prior to pregnancy. Of these cases, 95.5% corresponded to gestational diabetes mellitus (GDM), with 60.2% identified before 24 weeks and 35.3% after this period; additionally, 4.5% presented diabetes in pregnancy. The global prevalence of subtypes of hyperglycemia in pregnancy varies according to the specific type and geographic region. According to the medical literature, hyperglycemia in pregnancy affects approximately 16.9% of live births worldwide. Within this group, it is estimated that 16.0% of cases are attributed to diabetes in pregnancy, which includes both known diabetes and previously undiagnosed cases.[19] Regarding gestational diabetes, it is estimated to affect approximately 14% of pregnancies worldwide, although this figure can vary depending on risk factors and diagnostic methods used.[20] For instance, in Australia, the prevalence of hyperglycemia in pregnancy was reported at 13.1%, with 12.7% attributed to gestational diabetes and 0.4% to diabetes in pregnancy.[21] The study by Cosson et al. provides data on the prevalence of different subtypes of hyperglycemia in pregnancy, reporting 10.8% for early diagnosed gestational diabetes and 11.7% for later diagnosed gestational diabetes, while diabetes in pregnancy and early diagnosed diabetes have a prevalence of 0.6% each.[15] Furthermore, a systematic review aimed at comparing the prevalence of GDM according to the new IADPSG criteria versus the previous WHO criteria found that early screening increased prevalence by 60% and standard screening by 78%.[22] It is important to highlight that more than 90% of cases of hyperglycemia during pregnancy occur in low- and middleperpetuity.

It is made available under a CC-BY 4.0 International license .

19

income countries, underscoring the relevance of this condition from a public health and maternal-infant health perspective, particularly in developing countries.[19]

Explanation of Results

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

Several institutions agree that pregnant women with risk factors for diabetes should undergo early screening due to the high associated complication rates.[23] The IADPSG guidelines, adopted by the WHO in 2013, recommended using the same cut-off points between 24-28 weeks at any time during pregnancy.[24] However, it is crucial to differentiate between two conditions that may be detected during early screening: diabetes in pregnancy (pre-gestational) and other lesser hyperglycemic states that might later qualify as GDM but could merely be transient hyperglycemia during the first trimester. In 2015, an IADPSG panel suggested that fasting glucose values between 92 and 125 mg/dl should not be used for early screening, although they did not offer clear alternatives.[25] This recommendation was based on an Italian study showing that only 45% of patients with fasting glucose greater than 92 mg/dl during the first trimester were positive in the OGTT between 24-28 weeks, with an area under the curve (AUROC) of 0.614. [26] Similarly, a study in China recommended using a cut-off of 110 mg/dl instead of 92 mg/dl for the first trimester, showing a slight but consistent decline in fasting glucose from the first to the second trimester across the entire cohort.[27] In Simmons' clinical trial, only 67% of pregnant women with early GDM tested positive again in the OGTT at 24 weeks. [16] However, a fasting glucose level greater than 92 mg/dl may be considered a risk factor for the subsequent development of GDM, similar to pregestational body mass index.

perpetuity.

It is made available under a CC-BY 4.0 International license.

20

The main goal of screening is early detection to reduce the burden of subsequent disease, and not merely to diagnose prematurely without effects on relevant clinical outcomes. It has been documented that early GDM is associated with a higher risk of perinatal mortality, neonatal hypoglycemia, and increased insulin use compared to standard screening.[28] Nevertheless, it remains unclear whether the treatment of early gestational diabetes and its intensive management can be applied to all pregnant women or only those with certain risk factors.[29,30] This group of "early GDM" may represent a different range of phenotypes compared to those diagnosed after 24 weeks. A study comparing early GDM (before week 21) with late GDM (from week 24 onwards) found lower insulin sensitivity in the early GDM group, with similar beta cell dysfunction. However, the early screening group presented a higher pregestational body mass index (BMI),[31] It is important to discuss the impact of COVID-19, which appeared in the second year of recruitment, leading to a decrease in screening tests. However, when conditions improved, the program continued to follow the same algorithm, resulting in a notable increase in the prevalence of hyperglycemia, reaching up to 60% compared to 2019. Other studies have reported an increase ranging from 14% to 34%. [32,33] A possible explanation for this increase could be related to the rise in pregestational weight and gestational weight gain, which is linked to lifestyle changes such as reduced physical activity and increased stress, as well as changes in healthcare access and service utilization.[34–36]

Research Recommendations

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

Longitudinal studies or cost-effectiveness analyses are needed to evaluate the impact on perinatal outcomes for patients diagnosed with early gestational diabetes (GDM) or through standard screening to determine whether this trend is also observed in Latino populations. Furthermore, greater clarity is needed on whether early screening could be

implemented universally or based on risk factors (such as obesity or previous history of GDM). It is essential to define the exact timing during the first trimester, considering the physiological changes in pregnant women (before or after 16 weeks) or to use less strict diagnostic glycemic thresholds (recommended 110 mg/dl fasting). Regarding the diagnostic method, the oral glucose tolerance test (OGTT) and its variants are universally accepted. However, they are not easily applied in logistical terms for screening. Alternative diagnostic methods are being explored that offer better feasibility, such as hemoglobin A1c with a cut-off of 5.9%.[37] Additionally, multiple biological markers, such as C-reactive protein, adiponectin, and tumor necrosis factor, are being evaluated either in isolation or in combination with clinical variables as alternatives to the OGTT.[38]

Limitations and Strengths

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

Several limitations were identified in the present study. The cut-off points used for early gestational diabetes (GDM) lack long-term studies to support their impact and are based on IADPSG criteria. This may lead to an overestimation of GDM prevalence. Nonetheless, the World Health Organization (WHO) continues to recommend their use. Furthermore, the database did not include other variables that could explain differences in diagnostic prevalence, such as pregestational body mass index or previous history of gestational diabetes. However, we have sufficient statistical power to estimate differences between age groups. The COVID-19 pandemic also affected data collection and the performance of tests. Nevertheless, the tests that were conducted adhered to strict biosafety protocols. It is possible that GDM between 24 and 28 weeks is underrepresented, as the OGTT was not repeated for patients who tested negative in the early screening. Among the strengths of this study, we highlight the sample size, which

allows for prevalence estimates with an accuracy of 1.3%. Additionally, the OGTT was used, recognized as the gold standard for diagnosing gestational diabetes.

Conclusion

339

340

341

342

343

344

345

346

347

348

349

In pregnant women from four primary care centers in South Lima, it was found that one in seven (14.9%) presented hyperglycemia in pregnancy. GDM was 14.2%, and DIP was 0.7%. Early screening showed the highest proportion of GDM compared to standard or late screening. No differences in the prevalence of diabetes in pregnancy were found between the groups. Longitudinal studies are needed to determine whether this higher prevalence associated with early screening has repercussions on maternal-perinatal complications and whether it requires any form of treatment.

Bibliographics references

350

386

351 352 1. International Diabetes Federation, IDF Diabetes Atlas 10th edition, Bruselas, Béglica.; 353 2021. Available: https://diabetesatlas.org/idfawp/resourcefiles/2021/07/IDF Atlas 10th Edition 2021.pdf 354 355 2. Farrar D, Simmonds M, Bryant M, Sheldon TA, Tuffnell D, Golder S, et al. 356 Hyperglycaemia and risk of adverse perinatal outcomes: systematic review and metaanalysis. BMJ. 2016;354: i4694. doi:10.1136/bmj.i4694 357 Poolsup N, Suksomboon N, Amin M. Effect of Treatment of Gestational Diabetes 358 3. 359 Mellitus: A Systematic Review and Meta-Analysis. PLoS One. 2014;9: 1–9. doi:10.1371/journal.pone.0092485 360 361 4. Ferrara A. Increasing Prevalence of Gestational Diabetes Mellitus. A public health perspective. Diabetes Care. 2007;30: S141-146. doi:10.2337/dc07-s206 362 363 5. Instituto Nacional de Estadística e Informática. "Perú: Encuesta Demográfica y de Salud Familiar 2023 - Nacional y Departamental. Lima, Perú; 2024. Available: 364 365 https://www.inei.gob.pe/media/MenuRecursivo/publicaciones digitales/Est/Lib1950/libr 366 o.pdf 367 Thangaratinam S, Rogozińska E, Jolly K, Glinkowski S, Duda W, Borowiack E, et al. 6. Interventions to reduce or prevent obesity in pregnant women: a systematic review. 368 Health Technol Assess (Rocky). 2012;16. doi:10.3310/hta16310 369 370 7. Behboudi-Gandevani S, Amiri M, Yarandi RB, Tehrani FR. The impact of diagnostic criteria for gestational diabetes on its prevalence: a systematic review and meta -371 372 analysis. Diabetol Metab Syndr. 2019;11: 11. doi:10.1186/s13098-019-0406-1 373 8. Chen PY, Finkelstein EA, Ng MJ, Yap F, Yeo GSH, Rajadurai VS, et al. Incremental 374 Cost-Effectiveness Analysis of Gestational Diabetes Mellitus Screening Strategies in 375 Singapore. Asia Pac J Public Health. 2016;28: 15–25. doi:10.1177/1010539515612908 9. Werner E, Pettker C, Zuckerwise L, Reel M, Funai E, Henderson J, et al. Screening for 376 Gestational Diabetes Mellitus: Are the Criteria Proposed by the International Association 377 378 of the Diabetes and Pregnancy Study Groups Cost-Effective? Diabetes Care. 2012;35: 529-35. doi:10.2337/dc11-1643 379 10. Duran A, Saenz S, Torrejon MJ, Bordí U E, Del Valle L, Galindo M, et al. Introduction 380 of IADPSG criteria for the screening and diagnosis of gestational diabetes mellitus 381 382 results in improved pregnancy outcomes at a lower cost in a large cohort of pregnant women: The St. Carlos gestationaldiabetes study. Diabetes Care. 2014;37: 2442-2450. 383 doi:10.2337/dc14-0179 384 385 11. Hod M, Kapur A, Sacks D, Hadar E, Agarwal M, Di Renzo G, et al. The International

Federation of Gynecology and Obstetrics (FIGO) Initiative on gestational diabetes

- 387 mellitus: A pragmatic guide for diagnosis, management, and care. Int J Gynecol Obstet.
- 2015;131: S173-211. doi:10.1016/S0020-7292(15)30033-3 388
- 389 12. Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E. The role of aspirin
- dose on the prevention of preeclampsia and fetal growth restriction: systematic review 390
- and meta-analysis. Am J Obstet Gynecol. 2017;216: 110-120.e6. 391
- doi:10.1016/J.AJOG.2016.09.076 392
- Ye Y, Xiong Y, Zhou O, Xiao X, Li X, Early-Pregnancy Intermediate Hyperglycemia 393 13.
- 394 and Adverse Pregnancy Outcomes Among Women Without Gestational Diabetes. J Clin
- 395 Endocrinol Metab. 2021;107: e1541. doi:10.1210/CLINEM/DGAB841
- 14. Regnault N, Lebreton E, Tang L, Fosse-Edorh S, Barry Y, Olié V, et al. Maternal and 396
- neonatal outcomes according to the timing of diagnosis of hyperglycaemia in pregnancy: 397
- 398 a nationwide cross-sectional study of 695,912 deliveries in France in 2018. Diabetologia.
- 399 2024;67: 516-527. doi:10.1007/S00125-023-06066-4
- 400 15. Cosson E, Bentounes SA, Nachetergaele C, Berkane N, Pinto S, Sal M, et al. Prognosis
- Associated with Sub-Types of Hyperglycaemia in Pregnancy. J Clin Med. 2021;10. 401
- doi:10.3390/JCM10173904 402
- 403 16. Simmons D, Immanuel J, Hague WM, Teede H, Nolan CJ, Peek MJ, et al. Treatment of
- 404 Gestational Diabetes Mellitus Diagnosed Early in Pregnancy. New England Journal of
- 405 Medicine. 2023;388: 2132-2144.
- doi:10.1056/NEJMOA2214956/SUPPL FILE/NEJMOA2214956 DATA-406
- 407 SHARING.PDF
- 408 17. Agarwal MM, Dhatt GS, Othman Y. Gestational diabetes: differences between the
- 409 current international diagnostic criteria and implications of switching to IADPSG. J
- 410 Diabetes Complications. 2015;29: 544–549. doi:10.1016/J.JDIACOMP.2015.03.006
- 411 18. Larrabure-Torrealva GT, Martinez S, Luque-Fernandez MA, Sanchez SE, Mascaro PA,
- Ingar H, et al. Prevalence and risk factors of gestational diabetes mellitus: findings from 412
- a universal screening feasibility program in Lima, Peru. BMC Pregnancy Childbirth. 413
- 414 2018;18: 303. doi:https://doi.org/10.1186/s12884-018-1904-0
- 415 19. Guariguata L, Linnenkamp U, Beagley J, Whiting DR, Cho NH. Global estimates of the
- prevalence of hyperglycaemia in pregnancy. Diabetes Res Clin Pract. 2014;103: 176-416
- 185. doi:10.1016/J.DIABRES.2013.11.003 417
- 20. Sweeting A, Hannah W, Backman H, Catalano P, Feghali M, Herman WH, et al. 418
- 419 Epidemiology and management of gestational diabetes. Lancet. 2024;404: 175–192.
- doi:10.1016/S0140-6736(24)00825-0 420
- 421 21. Moses RG, Wong VCK, Lambert K, Morris GJ, San Gil F. The prevalence of
- 422 hyperglycaemia in pregnancy in Australia. Aust N Z J Obstet Gynaecol. 2016;56: 341–
- 423 345. doi:10.1111/AJO.12447
- 424 22. Saeedi M, Cao Y, Fadl H, Gustafson H, Simmons D. Increasing prevalence of
- 425 gestational diabetes mellitus when implementing the IADPSG criteria: A systematic

- 426 review and meta-analysis. Diabetes Res Clin Pract. 2021;172: 108642.
- doi:10.1016/J.DIABRES.2020.108642 427
- 428 23. Malaza N, Masete M, Adam S, Dias S, Nyawo T, Pheiffer C. A Systematic Review to
- 429 Compare Adverse Pregnancy Outcomes in Women with Pregestational Diabetes and
- Gestational Diabetes. Int J Environ Res Public Health. 2022;19: 10846. 430
- doi:10.3390/IJERPH191710846/S1 431
- 432 24. Organización Panamericana de la Salud. Criterios diagnósticos y clasificación de la
- hiperglucemia detectada por primera vez en el embarazo. 2016; 6. Available: 433
- 434 https://iris.paho.org/handle/10665.2/27870
- 25. McIntyre HD, Sacks DA, Barbour LA, Feig DS, Catalano PM, Damm P, et al. Issues 435
- 436 With the Diagnosis and Classification of Hyperglycemia in Early Pregnancy. Diabetes
- 437 Care. 2016;39: 53-54. doi:10.2337/DC15-1887
- Corrado F, D'Anna R, Cannata ML, Interdonato ML, Pintaudi B, Di Benedetto A. 438 26.
- 439 Correspondence between first-trimester fasting glycaemia, and oral glucose tolerance
- 440 test in gestational diabetes diagnosis. Diabetes Metab. 2012;38: 458–461.
- doi:10.1016/J.DIABET.2012.03.006 441
- 442 27. Zhu WW, Yang HX, Wei YM, Yan J, Wang ZL, Li XL, et al. Evaluation of the Value of
- 443 Fasting Plasma Glucose in the First Prenatal Visit to Diagnose Gestational Diabetes
- Mellitus in China. Diabetes Care. 2013;36: 586. doi:10.2337/DC12-1157 444
- 445 28. Immanuel J, Simmons D. Screening and Treatment for Early-Onset Gestational Diabetes
- Mellitus: a Systematic Review and Meta-analysis. Curr Diab Rep. 2017;17. 446
- 447 doi:10.1007/S11892-017-0943-7
- 29. Falavigna M, Schmidt MI, Trujillo J, Alves LF, Wendland ER, Torloni MR, et al. 448
- Effectiveness of gestational diabetes treatment: A systematic review with quality of 449
- 450 evidence assessment. Diabetes Res Clin Pract. 2012;98: 396–405.
- doi:10.1016/j.diabres.2012.09.002 451
- 452 30. Behboudi-Gandevani S, Bidhendi-Yarandi R, Panahi MH, Vaismoradi M. The Effect of
- Mild Gestational Diabetes Mellitus Treatment on Adverse Pregnancy Outcomes: A 453
- 454 Systemic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2021;12: 640004.
- 455 doi:10.3389/FENDO.2021.640004/BIBTEX
- 456 31. Bozkurt L, Göbl CS, Pfligl L, Leitner K, Bancher-Todesca D, Luger A, et al.
- Pathophysiological Characteristics and Effects of Obesity in Women With Early and 457
- Late Manifestation of Gestational Diabetes Diagnosed by the International Association 458
- of Diabetes and Pregnancy Study Groups Criteria. J Clin Endocrinol Metab. 2015;100: 459
- 1113-1120. doi:10.1210/JC.2014-4055 460
- 32. Auger N, Wei SQ, Dayan N, Ukah U V., Quach C, Lewin A, et al. Impact of Covid-19 461
- on rates of gestational diabetes in a North American pandemic epicenter. Acta Diabetol. 462
- 2023;60: 257–264. doi:10.1007/S00592-022-02000-Z 463

33. Zanardo V, Tortora D, Sandri A, Severino L, Mesirca P, Straface G. COVID-19 464 465 pandemic: Impact on gestational diabetes mellitus prevalence. Diabetes Res Clin Pract. 2022;183. doi:10.1016/j.diabres.2021.109149 466 467 34. Rhou YJJ, Elhindi J, Melov SJ, Cheung NW, Pasupathy D. Indirect effects of the 468 COVID-19 pandemic on risk of gestational diabetes and factors contributing to increased 469 risk in a multiethnic population: a retrospective cohort study. BMC Pregnancy Childbirth. 2023;23: 1-10. doi:10.1186/S12884-023-05659-6/TABLES/4 470 35. Nour TY, Altintaş KH. Effect of the COVID-19 pandemic on obesity and it is risk 471 472 factors: a systematic review. BMC Public Health. 2023;23: 1-24. doi:10.1186/S12889-473 023-15833-2/FIGURES/1 474 36. Pinedo-Soria A, Pasco-Ramírez F, Samir Cubas W. Ganancia de peso durante el 475 confinamiento por la COVID-19 en la población peruana. Revista Médica Herediana. 2022;33: 72-73. doi:10.20453/RMH.V33I1.4172 476 477 37. Hughes RCE, Moore MP, Gullam JE, Mohamed K, Rowan J. An Early Pregnancy 478 HbA1c ≥5.9% (41 mmol/mol) Is Optimal for Detecting Diabetes and Identifies Women at Increased Risk of Adverse Pregnancy Outcomes. Diabetes Care. 2014;37: 2953–2959. 479 doi:10.2337/DC14-1312 480 481 38. Huhn EA, Rossi SW, Hoesli I, Göbl CS. Controversies in Screening and Diagnostic Criteria for Gestational Diabetes in Early and Late Pregnancy. Front Endocrinol 482 (Lausanne). 2018;9: 411579. doi:10.3389/FENDO.2018.00696/BIBTEX 483 484

Supplementary tables

486

487

- Table S1. Results of basal glycemia, 60 minutes and 120 minutes of OGTT according 488
- to clinical characteristics in pregnant women 489
- Table S2. Characteristics of patients with gestational diabetes 490
- Tabla S3. Carácterísticas de las pacientescon Diabetes pregestacional. 492

